These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23234110)

  • 1. [First WARFASA, now ASPIRE. The new career of ASS in long-term thromboembolism prevention].
    Einecke D
    MMW Fortschr Med; 2012 Nov; 154(20):18. PubMed ID: 23234110
    [No Abstract]   [Full Text] [Related]  

  • 2. Aspirin in the secondary prevention of unprovoked thromboembolism: the WARFASA and ASPIRE studies.
    Birocchi S; Scannella E; Ferrari L; Podda GM;
    Intern Emerg Med; 2013 Dec; 8(8):757-60. PubMed ID: 23744554
    [No Abstract]   [Full Text] [Related]  

  • 3. [Aspirin for secondary prevention of venous thromboembolism. WARFASA: far from being conclusive].
    Delluc A; Lacut K; Mottier D
    Rev Med Interne; 2013 Feb; 34(2):69-72. PubMed ID: 23154111
    [No Abstract]   [Full Text] [Related]  

  • 4. [Anticoagulation and antiaggregation in cardiac patients].
    Meyer BJ
    Ther Umsch; 2003 Jan; 60(1):27-32. PubMed ID: 12638475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summaries for patients. Occurrence of venous thromboembolism in women taking low-dose aspirin.
    Ann Intern Med; 2007 Oct; 147(8):I34. PubMed ID: 17938386
    [No Abstract]   [Full Text] [Related]  

  • 6. [Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
    Stiefelhagen P
    MMW Fortschr Med; 2010 Mar; 152(12):12-4. PubMed ID: 20394161
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial.
    Glynn RJ; Ridker PM; Goldhaber SZ; Buring JE
    Ann Intern Med; 2007 Oct; 147(8):525-33. PubMed ID: 17938390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antiaggregation: aspirin].
    Eichenberger A; Pontiggia L; Beer JH
    Ther Umsch; 2003 Jan; 60(1):15-8. PubMed ID: 12638472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin and recurrent venous thromboembolism.
    Prandoni P; Noventa F; Milan M
    Phlebology; 2013 Mar; 28 Suppl 1():99-104. PubMed ID: 23482543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative aspirin management after POISE-2: some answers, but questions remain.
    Gerstein NS; Carey MC; Cigarroa JE; Schulman PM
    Anesth Analg; 2015 Mar; 120(3):570-575. PubMed ID: 25695574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should aspirin be continued in patients started on warfarin?
    Larson RJ; Fisher ES
    J Gen Intern Med; 2004 Aug; 19(8):879-86. PubMed ID: 15242475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What anticoagulant therapy should be used for what form of atrial fibrillation?].
    Frantz E
    Dtsch Med Wochenschr; 2000 Apr; 125 Suppl 1():S10-1. PubMed ID: 10818997
    [No Abstract]   [Full Text] [Related]  

  • 13. [Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks].
    Prisco D
    Haematologica; 2001 Sep; 86(9 Suppl):12-3. PubMed ID: 11759618
    [No Abstract]   [Full Text] [Related]  

  • 14. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
    Weitz JI; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Holberg G; Kakkar A; Lensing AW; Prins M; Haskell L; van Bellen B; Verhamme P; Wells PS; Prandoni P;
    Thromb Haemost; 2015 Aug; 114(3):645-50. PubMed ID: 25994838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of anticoagulants. Therapy and prophylaxis for thromboembolic phenomena.
    Quick D; Trowbridge AA
    Postgrad Med; 1984 Dec; 76(8):151-4, 156, 158-62. PubMed ID: 6504795
    [No Abstract]   [Full Text] [Related]  

  • 16. Guidelines for the use of thrombolytic therapy. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology.
    Ludlam CA; Bennett B; Fox KA; Lowe GD; Reid AW
    Blood Coagul Fibrinolysis; 1995 May; 6(3):273-85. PubMed ID: 7654941
    [No Abstract]   [Full Text] [Related]  

  • 17. Stroke prevention: antiplatelet and antithrombolytic therapy.
    Diener HC
    Haemostasis; 2000; 30 Suppl 3():14-26. PubMed ID: 11182625
    [No Abstract]   [Full Text] [Related]  

  • 18. [Low-dosage ASA should not be given as primary prevention. The risk is greater than the benefit--also in high risk of cardiovascular disease].
    Håkansson J; Hernborg A
    Lakartidningen; 2010 Feb 3-9; 107(5):260-2. PubMed ID: 20297567
    [No Abstract]   [Full Text] [Related]  

  • 19. Patients with Peripheral Artery Disease in the COMPASS Trial.
    Kruger PC; Anand SS; de Vries TAC; Eikelboom JW
    Eur J Vasc Endovasc Surg; 2018 Dec; 56(6):772-773. PubMed ID: 30213508
    [No Abstract]   [Full Text] [Related]  

  • 20. [Recommendations for peri-procedural thrombocyte aggregation inhibition].
    Sauer H; Leschke M
    Dtsch Med Wochenschr; 2006 Feb; 131(8):400-2. PubMed ID: 16479474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.